Details of the Drug Combination

General Information of Drug Combination (ID: DCYEWT2)

Drug Combination Name
Indazole derivative 5 BIO-300
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R BIO-300   DMJ7NVI
Small molecular drug N.A.
High-throughput Screening Result Testing Cell Line: K-562
Zero Interaction Potency (ZIP) Score: 8.48
Bliss Independence Score: 4.43
Loewe Additivity Score: 5.07
LHighest Single Agent (HSA) Score: 7.58

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [4]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCVXFIO MOLT-4 Investigative [1]
Clear cell renal cell carcinoma DCKK021 TK-10 Investigative [1]
Clear cell renal cell carcinoma DC5E3QL CAKI-1 Investigative [1]
Glioblastoma DCPWJ5V SNB-75 Investigative [1]
Glioma DCNOQ2A SF-539 Investigative [1]
Colon carcinoma DCX77FK KM12 Investigative [5]
Adenocarcinoma DCQL98S SW-620 Investigative [6]
Adenocarcinoma DCF9LRM HCC-2998 Investigative [6]
Amelanotic melanoma DCO560Z MDA-MB-435 Investigative [6]
Large cell lung carcinoma DC272VJ NCI-H460 Investigative [6]
Lung adenocarcinoma DCHNDU0 NCI-H522 Investigative [6]
Minimally invasive lung adenocarcinoma DCVJNI1 NCI-H322M Investigative [6]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
6 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.